IFLR1000

Concordia Healthcare $3.5 billion acquisition of Amdipharm Mercury

21/10/2015
Acquisition finance, Public acquisition
Select tab

$ 3.5 billion

Completed

21/10/2015

Overview:

  • Canadian pharmaceutical company Concordia Healthcare has completed its $3.5 billion acquisition of Amdipharm Mercury.
  • Amdipharm was sold by European private equity firm Cinven.
  • Concordia is funding the deal through cash, common shares, and earn-out payables.

Kurt Stumpo - Journalist

Jurisdictions:

Canada
United States
United Kingdom
Channel Islands: Jersey

Deal types:

Acquisition finance
Public acquisition

Practice area:

M&A

Industry sector:

Pharmaceuticals and life sciences

Firms:
Appleby

Party: Cinven (Seller)

Lawyer: Andrew Weaver

Clifford Chance

Party: Cinven (Seller)

Lawyers: Jonny Myers, Michael Dakin

Fasken

Party: Concordia Healthcare (Acquirer)

Lawyers: John Sabetti, Jon Holmstrom, Rubin Rapuch

Jones Day

Party: Amdipharm Mercury (Management)

Mourant Ozannes

Party: Cinven (Seller)

Lawyer: James Hill

Sullivan & Cromwell

Party: Concordia Healthcare (Acquirer)

Lawyers: John Estes, Matthew Hurd, Robert Buckholz, Vanessa Blackmore

Torys

Party: Cinven (Seller)

Lawyers: Andrew Beck, Mile Kurta

William Fry

Party: Concordia Healthcare (Borrower)

Related deals